| Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers. | |
| | |
MedLine Citation:
|
PMID: 1717776 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of the present study was to look for possible additive or synergistic effects of the combined oral administration of a single dose of an angiotensin converting enzyme (ACE) inhibitor, benazepril (10 mg) (B), and a long-acting vasodilator, cadralazine (5 mg) (C), on blood pressure, arterial parameters, and active plasma renin. The study was carried out in eight normotensive subjects according to a double-blind, randomized, placebo-controlled, crossover design. Blood pressure (BP), heart rate, humeral artery diameter (D), carotid-femoral pulse-wave velocity (PWV), finger-pulse ratio (FPR), and plasma active renin (PAR) were measured at baseline and every 2 h over 8 h. A significant treatment effect was observed for supine and tilted BP, FPR, PWV, and PAR. The largest decrease in supine systolic and diastolic BP was observed with the combination (10.0 +/- 6.9/7.2 +/- 3.7 mm Hg). Six hours after drug intake, the mean changes in FPR were 0.05 +/- 0.24 (P), -0.06 +/- 0.30 (C), 0.13 +/- 0.32 (B), and 0.28 +/- 0.34 (B + C), and the mean changes in PWV were 0.14 +/- 0.66 m/s (P), 0.09 +/- 0.54 m/s (C), -0.29 +/- 0.50 m/s (B), and -0.55 +/- 0.48 m/s (B + C). PAR was more markedly augmented with the combination of the two drugs (142 +/- 40 pg/ml) than with benazepril alone (90 +/- 62 pg/ml). It was concluded that a single noneffective dose of a vasodilator administered together with an ACE inhibitor in normotensives can lower blood pressure and increase arterial compliance and plasma active renin. |
| | |
Authors:
|
P Brunel; T T Guyene; H Howald; J Ménard |
Related Documents
:
|
16108036 - A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spon... 402166 - The effects of edta and egta on renin secretion. 18362226 - Orally active aminopeptidase a inhibitors reduce blood pressure: a new strategy for tre... 1093756 - Effect of salt depletion and propranolol on blood pressure and plasma renin activity in... 16557156 - Blood volume measurements using an integrated fiberoptic monitoring system in a porcine... 12618156 - Validation of the welch allyn 'vital signs' blood pressure measurement device in pregna... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 18 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 1991 Aug |
Date Detail:
|
Created Date: 1991-11-08 Completed Date: 1991-11-08 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 175-81 Citation Subset: IM |
Affiliation:
|
Pharma Research and Development, CIBA-GEIGY Limited, Basel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Angiotensin-Converting Enzyme Inhibitors / pharmacology* Antihypertensive Agents / pharmacology* Benzazepines / pharmacology* Blood Pressure / drug effects* Double-Blind Method Drug Synergism Heart Rate / drug effects* Humans Male Pilot Projects Posture Pyridazines / pharmacology* Random Allocation Renin / blood |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzazepines; 0/Pyridazines; 64241-34-5/cadralazine; 86541-75-5/benazepril; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Platelet-derived serotonin, the endothelium, and cardiovascular disease.
Next Document: The positive inotropic drugs DPI 201-106, BDF 9148, and veratridine increase ouabain toxicity and [3...